Ebrahim Mazloomi

Ebrahim Mazloomi

Auto-generated profile, based on publicly available information

Ebrahim Mazloomi

Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Microbes and Infection
Verified
Journal Article
Closed access
NJNima Hosseini Jazani
Nima Hosseini Jazani
MKMojtaba Karimzad
Mojtaba Karimzad
EMEbrahim Mazloomi
Ebrahim Mazloomi
MSMohammad Sohrabpour
Mohammad Sohrabpour
ZHZuhair Muhammad Hassan
Zuhair Muhammad Hassan
SSShahram Shahabi
Shahram Shahabi


1 June 2011 in Immunobiology
Verified
Journal Article
Closed access
NJNima Hosseini Jazani
Nima Hosseini Jazani
SPSomayeh Parsania
Somayeh Parsania
MSMohammad Sohrabpour
Mohammad Sohrabpour
EMEbrahim Mazloomi
Ebrahim Mazloomi
MKMojtaba Karimzad
Mojtaba Karimzad
SSShahram Shahabi
Shahram Shahabi

5 November 2010 in FEMS Immunology & Medical Microbiology
Verified
Journal Article
Open access
PDF file
NJNima Hosseini Jazani
Nima Hosseini Jazani
MSMohammad Sohrabpour
Mohammad Sohrabpour
EMEbrahim Mazloomi
Ebrahim Mazloomi
SSShahram Shahabi
Shahram Shahabi
In the current study, we tested the efficacy of the mixture of naloxone, an opioid receptor antagonist, and alum, as a new adjuvant, in the induction

1 October 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
EMEbrahim Mazloomi
Ebrahim Mazloomi
BIBehrooz Ilkhanizadeh
Behrooz Ilkhanizadeh
AZAhad Zare
Ahad Zare
AMAdel Mohammadzadeh
Adel Mohammadzadeh
NDNowruz Delirezh
Nowruz Delirezh
SSShahram Shahabi
Shahram Shahabi

13 June 2014 in Immunological Investigations
Verified
Journal Article
Closed access
SSShahram Shahabi
Shahram Shahabi
HAHakim Azizi
Hakim Azizi
EMEbrahim Mazloomi
Ebrahim Mazloomi
KTKhosrow Hazrati Tappeh
Khosrow Hazrati Tappeh
SSShahram Seyedi
Shahram Seyedi
HHHabib Mohammadzadeh Hajipirloo
Habib Mohammadzadeh Hajipirloo
We previously showed that the mixture of naltrexone (NLT), a general opioid antagonist, and alum, acts as an effective adjuvant in enhancing vaccine-induced T helper 1 (TH1) humoral immune responses against Toxoplasma gondii. Here, we tested the efficacy of the mixture of NLT and alum in the induction of immunity in response to blood stages of Plasmodium berghei (BSPb) as a model vaccine. BALB/c mice were divided into five vaccination groups. Mice in the experimental groups received the BSPb vaccine alone or in combination with the adjuvant alum, NLT or the alum-NLT mixture. Mice in the control group received PBS. All mice were immunized on days 0, 7 and 14. Two weeks after the last immunization, immune responses to Plasmodium berghei were assessed. Our results indicated that including the alum-NLT mixture as an adjuvant during vaccination increased the ability of the BSPb vaccine to enhance lymphocyte proliferation, shifted the immune response towards a TH1 profile and increased Plasmodium berghei-specific IgG2a. This resulted in improved protective immunity against Plasmodium berghei. In conclusion, administering alum-NLT mixture in combination with the BSPb vaccine enhanced the vaccine-induced immunity, and shifted the immune response toward TH1 pattern.